Cargando…
An overview of resistance to chemotherapy in osteosarcoma and future perspectives
Osteosarcoma (OS) is the most common type of bone sarcoma. Despite the availability of multimodal treatment with surgery and chemotherapy, the clinical results remain unsatisfactory. The main reason for the poor outcomes in patients with OS is the development of resistance to methotrexate, cisplatin...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
OAE Publishing Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511812/ https://www.ncbi.nlm.nih.gov/pubmed/36176756 http://dx.doi.org/10.20517/cdr.2022.18 |
_version_ | 1784797720487133184 |
---|---|
author | Garcia-Ortega, Dorian Yarih Cabrera-Nieto, Sara Aileen Caro-Sánchez, Haydee Sarai Cruz-Ramos, Marlid |
author_facet | Garcia-Ortega, Dorian Yarih Cabrera-Nieto, Sara Aileen Caro-Sánchez, Haydee Sarai Cruz-Ramos, Marlid |
author_sort | Garcia-Ortega, Dorian Yarih |
collection | PubMed |
description | Osteosarcoma (OS) is the most common type of bone sarcoma. Despite the availability of multimodal treatment with surgery and chemotherapy, the clinical results remain unsatisfactory. The main reason for the poor outcomes in patients with OS is the development of resistance to methotrexate, cisplatin, doxorubicin, and ifosfamide. Molecular and cellular mechanisms associated with resistance to chemotherapy include DNA repair and cell-cycle alterations, enhanced drug efflux, increased detoxification, resistance to apoptosis, autophagy, tumor extracellular matrix, and angiogenesis. This versatility of cells to generate chemoresistance has motivated the use of anti-angiogenic therapy based on tyrosine kinase inhibitors. This approach has shown that other therapies, along with standard chemotherapy, can improve responses to therapy in patients with OS. Moreover, microRNAs may act as predictors of drug resistance in OS. This review provides insight into the molecular and cellular mechanisms involved in the development of resistance during the treatment of OS and discusses promising novel therapies (e.g., afatinib and palbociclib) for overcoming resistance to chemotherapy in OS. |
format | Online Article Text |
id | pubmed-9511812 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | OAE Publishing Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95118122022-09-28 An overview of resistance to chemotherapy in osteosarcoma and future perspectives Garcia-Ortega, Dorian Yarih Cabrera-Nieto, Sara Aileen Caro-Sánchez, Haydee Sarai Cruz-Ramos, Marlid Cancer Drug Resist Review Osteosarcoma (OS) is the most common type of bone sarcoma. Despite the availability of multimodal treatment with surgery and chemotherapy, the clinical results remain unsatisfactory. The main reason for the poor outcomes in patients with OS is the development of resistance to methotrexate, cisplatin, doxorubicin, and ifosfamide. Molecular and cellular mechanisms associated with resistance to chemotherapy include DNA repair and cell-cycle alterations, enhanced drug efflux, increased detoxification, resistance to apoptosis, autophagy, tumor extracellular matrix, and angiogenesis. This versatility of cells to generate chemoresistance has motivated the use of anti-angiogenic therapy based on tyrosine kinase inhibitors. This approach has shown that other therapies, along with standard chemotherapy, can improve responses to therapy in patients with OS. Moreover, microRNAs may act as predictors of drug resistance in OS. This review provides insight into the molecular and cellular mechanisms involved in the development of resistance during the treatment of OS and discusses promising novel therapies (e.g., afatinib and palbociclib) for overcoming resistance to chemotherapy in OS. OAE Publishing Inc. 2022-06-23 /pmc/articles/PMC9511812/ /pubmed/36176756 http://dx.doi.org/10.20517/cdr.2022.18 Text en © The Author(s) 2022. https://creativecommons.org/licenses/by/4.0/© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Review Garcia-Ortega, Dorian Yarih Cabrera-Nieto, Sara Aileen Caro-Sánchez, Haydee Sarai Cruz-Ramos, Marlid An overview of resistance to chemotherapy in osteosarcoma and future perspectives |
title | An overview of resistance to chemotherapy in osteosarcoma and future perspectives |
title_full | An overview of resistance to chemotherapy in osteosarcoma and future perspectives |
title_fullStr | An overview of resistance to chemotherapy in osteosarcoma and future perspectives |
title_full_unstemmed | An overview of resistance to chemotherapy in osteosarcoma and future perspectives |
title_short | An overview of resistance to chemotherapy in osteosarcoma and future perspectives |
title_sort | overview of resistance to chemotherapy in osteosarcoma and future perspectives |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511812/ https://www.ncbi.nlm.nih.gov/pubmed/36176756 http://dx.doi.org/10.20517/cdr.2022.18 |
work_keys_str_mv | AT garciaortegadorianyarih anoverviewofresistancetochemotherapyinosteosarcomaandfutureperspectives AT cabreranietosaraaileen anoverviewofresistancetochemotherapyinosteosarcomaandfutureperspectives AT carosanchezhaydeesarai anoverviewofresistancetochemotherapyinosteosarcomaandfutureperspectives AT cruzramosmarlid anoverviewofresistancetochemotherapyinosteosarcomaandfutureperspectives AT garciaortegadorianyarih overviewofresistancetochemotherapyinosteosarcomaandfutureperspectives AT cabreranietosaraaileen overviewofresistancetochemotherapyinosteosarcomaandfutureperspectives AT carosanchezhaydeesarai overviewofresistancetochemotherapyinosteosarcomaandfutureperspectives AT cruzramosmarlid overviewofresistancetochemotherapyinosteosarcomaandfutureperspectives |